JOP20210151A1 - أجسام مضادة ناهضة لـ flt3 واستخداماتها - Google Patents

أجسام مضادة ناهضة لـ flt3 واستخداماتها

Info

Publication number
JOP20210151A1
JOP20210151A1 JOP/2021/0151A JOP20210151A JOP20210151A1 JO P20210151 A1 JOP20210151 A1 JO P20210151A1 JO P20210151 A JOP20210151 A JO P20210151A JO P20210151 A1 JOP20210151 A1 JO P20210151A1
Authority
JO
Jordan
Prior art keywords
agonist antibodies
flt3
flt3 agonist
agonistic antibodies
antibodies
Prior art date
Application number
JOP/2021/0151A
Other languages
English (en)
Inventor
Melissa Beilschmidt
Phil Gobeil
Arif Jetha
Johan Fransson
Dorothea Maetzel
Original Assignee
Boehringer Ingelheim Io Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Io Canada Inc filed Critical Boehringer Ingelheim Io Canada Inc
Publication of JOP20210151A1 publication Critical patent/JOP20210151A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

يتعلق الاختراع بوصف أجسام مضادة ناهضة لـ FLT3. هذه الأجسام المضادة الناهضة مفيدة لتمديد الخلايا التغصنية ومعالجة السرطان.
JOP/2021/0151A 2018-12-18 2019-12-17 أجسام مضادة ناهضة لـ flt3 واستخداماتها JOP20210151A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862781213P 2018-12-18 2018-12-18
PCT/IB2019/001437 WO2020128638A1 (en) 2018-12-18 2019-12-17 Flt3 agonist antibodies and uses thereof

Publications (1)

Publication Number Publication Date
JOP20210151A1 true JOP20210151A1 (ar) 2023-01-30

Family

ID=71101095

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2021/0151A JOP20210151A1 (ar) 2018-12-18 2019-12-17 أجسام مضادة ناهضة لـ flt3 واستخداماتها

Country Status (21)

Country Link
US (1) US20220025055A1 (ar)
EP (1) EP3902836A4 (ar)
JP (1) JP2022513961A (ar)
KR (1) KR20210111785A (ar)
CN (1) CN113544152A (ar)
AU (1) AU2019404098A1 (ar)
BR (1) BR112021010948A2 (ar)
CA (1) CA3120063A1 (ar)
CL (1) CL2021001312A1 (ar)
CO (1) CO2021007689A2 (ar)
CR (1) CR20210327A (ar)
DO (1) DOP2021000114A (ar)
EA (1) EA202191650A1 (ar)
EC (1) ECSP21044672A (ar)
IL (1) IL283922A (ar)
JO (1) JOP20210151A1 (ar)
MA (1) MA54614A (ar)
MX (1) MX2021007339A (ar)
PE (1) PE20211474A1 (ar)
SG (1) SG11202104352XA (ar)
WO (1) WO2020128638A1 (ar)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3990476A1 (en) 2019-06-25 2022-05-04 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635388A (en) * 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
DE19727814C1 (de) * 1997-06-30 1998-10-01 Univ Eberhard Karls Anitkörper 4G8B4B12
AR071891A1 (es) * 2008-05-30 2010-07-21 Imclone Llc Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
EP3165236B1 (en) * 2009-08-28 2022-03-16 Teva Pharmaceuticals International GmbH Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
DK2516468T3 (en) * 2009-12-23 2016-05-23 Synimmune Gmbh ANTI-FLT3 ANTIBODIES AND METHODS FOR USING THESE
MY178919A (en) * 2015-03-09 2020-10-23 Agensys Inc Antibody drug conjugates (adc) that bind to flt3 proteins
EP3630841A1 (en) * 2017-06-02 2020-04-08 Pfizer Inc. Antibodies specific for flt3 and their uses
BR112019024604A2 (pt) * 2017-06-02 2020-06-23 Pfizer Inc. Receptores de antígenos quiméricos que alvejam flt3

Also Published As

Publication number Publication date
PE20211474A1 (es) 2021-08-05
DOP2021000114A (es) 2021-09-30
JP2022513961A (ja) 2022-02-09
SG11202104352XA (en) 2021-05-28
CO2021007689A2 (es) 2021-06-21
CL2021001312A1 (es) 2022-01-07
AU2019404098A1 (en) 2021-05-27
WO2020128638A8 (en) 2021-06-03
CR20210327A (es) 2021-09-27
MX2021007339A (es) 2021-07-15
MA54614A (fr) 2022-03-30
IL283922A (en) 2021-07-29
KR20210111785A (ko) 2021-09-13
BR112021010948A2 (pt) 2021-08-31
CN113544152A (zh) 2021-10-22
EP3902836A4 (en) 2022-08-31
WO2020128638A1 (en) 2020-06-25
CA3120063A1 (en) 2020-06-25
ECSP21044672A (es) 2021-09-30
US20220025055A1 (en) 2022-01-27
EP3902836A1 (en) 2021-11-03
EA202191650A1 (ru) 2021-10-22

Similar Documents

Publication Publication Date Title
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
PH12020551923A1 (en) Methods and compositions for treating cancer
PH12018500815A1 (en) Antibody conjugates comprising toll-like receptor agonist
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
MY194619A (en) Glucocorticoid receptor agonist and immunoconjugates thereof
PH12021550152A1 (en) Anti-cd112r compositions and methods
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
SG10201809668TA (en) Anti-her2 antibodies and immunoconjugates
NZ731467A (en) Anti-tim3 antibodies and methods of use
SG10201804931QA (en) Anti-cll-1 antibodies and immunoconjugates
WO2018081648A8 (en) ANTI-MIC ANTIBODIES AND METHODS OF USE
NZ735778A (en) Kappa myeloma antigen chimeric antigen receptors and uses thereof
CR20200239A (es) Agonista del receptor de glucocorticoides e inmunoconjugados de este
MX2020010951A (es) Anticuerpos anti-hla-g y utilizacion de los mismos.
CR20200404A (es) Anticuerpos anti-klk5 y métodos de uso
PH12020551716A1 (en) Anti-ror antibody constructs
MX2022003967A (es) Composiciones y metodos para la liberacion prolongada de antagonistas de la hormona liberadora de gonadotropina (gnrh).
MX2021002616A (es) Anticuerpos agonistas anti receptor desencadenante expresado en celulas mieloides 2 (trem-2).
MX2022014457A (es) Formulaciones de inmunoconjugado anti-cd79b estables.
MX2020004666A (es) Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares.
AU201715153S (en) Ramp
CR20210327A (es) Anticuerpos agonistas de flt3 y usos de estos
MX2020012990A (es) Formulaciones de tegavivint y compuestos relacionados.
MX2019010060A (es) Composiciones y metodo para tratar cancer.